These Analysts Revise Price Targets On Biogen Following Q1 Results

Biogen Inc. BIIB reported results for its first quarter.

Biogen reported first-quarter revenue of $2.46 billion, which beat average estimates of $2.34 billion. The company reported adjusted earnings of $3.40 per share, which beat estimates of $3.28 per share.

The FDA approved Biogen and Ionis Pharmaceuticals’ tofersen, which will be sold under the brand name Qalsody.
Biogen shares fell 3.6% to close at $282.41 on Tuesday and added 0.3% in today’s pre-market trading session.

These analysts made changes to their price targets on Biogen following earnings announcement.

  • Atlantic Equities cut the price target on Biogen from $295 to $282. Atlantic Equities analyst Steve Chesney maintained a Neutral rating.
  • Needham slashed the price target on Biogen from $325 to $321. Needham analyst Ami Fadia maintained a Buy rating
  • Morgan Stanley increased the Biogen price target from $349 to $371. Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on the stock.
  • Barclays lowered the price target from $307 to $302. Barclays analyst Carter Gould maintained Biogen with an Equal-Weight.
  • Oppenheimer raised the price target from $310 to $325. Oppenheimer analyst Jay Olson maintained Biogen with an Outperform.

 

Now Read This: Microsoft, Boeing And 3 Stocks To Watch Heading Into Wednesday

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPrice TargetPre-Market OutlookMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!